Sutro Biopharma Inc., of South San Francisco, said that a study published in the July 2010 issue of Biotechnology and Bioengineering showed that its biochemical protein synthesis technology platform enabled fast, high-yield protein synthesis and scale-up. In the study, a bioactive cytokine human granulocyte-macrophage colony-stimulating factor was produced at titers of 700 mg/L in 10 hours from frozen extract of Sutro's E.coli-based open cell-free synthesis system.